



an Open Access Journal by MDPI

## Advanced Research in the Pathophysiology and Treatment of Diabetes Mellitus

Guest Editor:

### Dr. Chrysi Koliaki

First Propaedeutic Department of  
Internal Medicine and Diabetes  
Center, National Kapodistrian  
University of Athens, Laiko  
University Hospital, 11527  
Athens, Greece

Deadline for manuscript  
submissions:

**closed (30 April 2024)**

### Message from the Guest Editor

Diabetes mellitus, the contemporary metabolic pandemic, represents a complex multifactorial syndrome characterized by abnormalities in every single aspect of cellular energy metabolism. Type 1 diabetes mellitus (T1DM) is associated with reduced endogenous insulin secretion as a result of progressive autoimmune destruction of insulin-producing pancreatic  $\beta$ -cells. Type 2 diabetes mellitus (T2DM) is associated with both insulin resistance and defective insulin secretion. Beyond T1DM and T2DM, distinct phenotypes of diabetes with varying degrees of insulin resistance and pancreatic  $\beta$ -cell defects have been characterized in the literature.

The aim of this special issue is to provide a platform for sharing all the novel insights into the pathophysiology and treatment of diabetes mellitus. Both original research and comprehensive review articles on this topic are invited for submission. The aim of this special issue is to provide a platform for sharing all the novel insights into the pathophysiology and treatment of diabetes mellitus. Both original research and comprehensive review articles on this topic are invited for submission.



[mdpi.com/si/157284](https://mdpi.com/si/157284)

# Special Issue



an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research  
Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA  
2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPlus / SciFinder*, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

## Contact Us

*Biomedicines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](http://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
X@Biomed\_MDPI